Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose versus standard-dose prednisolone for relapse of steroid-sensitive idiopathic nephrotic syndrome in children
ACTRN12624001201561Phase 4Not yet recruiting
- Sponsor
- Flinders University
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of prednisolone in Idiopathic nephrotic syndrome (INS) and nephrosis (4 arms), sponsored by Flinders University. Primary endpoints: Time from relapse to remission and Time from remission to next relapse. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
prednisolone
03
Conditions
Idiopathic nephrotic syndrome (INS)nephrosis
Beyond the preview
Go deeper on ACTRN12624001201561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001201561.